Changes of Prothrombin Fragment 1+2 (F 1+2) as a Function of Increasing Intensity of Oral Anticoagulation

Armando Tripodi; Marco Cattaneo; Alfredo Molteni; Bruno M. Cesana; Pier Mannuccio Mannucci

doi:10.1055/s-0037-1614947

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(03): 571-573
DOI: 10.1055/s-0037-1614947

Review Articles

Schattauer GmbH

Changes of Prothrombin Fragment 1+2 (F 1+2) as a Function of Increasing Intensity of Oral Anticoagulation

Considerations on the Suitability of F 1+2 to Monitor Oral Anticoagulant Treatment

Armando Tripodi

¹From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, University and the Epidemiology Unit, IRCCS Maggiore Hospital, Milano, Italy

,

Marco Cattaneo

¹From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, University and the Epidemiology Unit, IRCCS Maggiore Hospital, Milano, Italy

,

Alfredo Molteni

¹From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, University and the Epidemiology Unit, IRCCS Maggiore Hospital, Milano, Italy

,

Bruno M. Cesana

¹From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, University and the Epidemiology Unit, IRCCS Maggiore Hospital, Milano, Italy

,

Pier Mannuccio Mannucci

¹From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, University and the Epidemiology Unit, IRCCS Maggiore Hospital, Milano, Italy

› Institutsangaben

Abstract

Summary

Plasma F 1+2 levels, the activation peptide originating from the factor Xa-mediated activation of prothrombin, increase in many clinical conditions associated with hypercoagulability and decrease in patients on oral anticoagulant treatment (OAT). However, the usefulness of F 1+2 measurement to monitor OAT has not yet been investigated in clinical studies. Before those studies are attempted, the plausibility of its implementation in the laboratory control of OAT should be evaluated. In this respect, a thorough investigation of the pattern of changes of F 1+2 as a function of increased intensity of anticoagulation expressed as International Normalized Ratio is essential. One hundred and thirty-two patients on long-term warfarin treatment were recruited to cover 8 ranges of anticoagulation from <1.5 to 9.0 INR. F 1+2 was measured in batch on frozen plasma and INR was determined on fresh plasma. The relationship of F 1+2 vs. INR showed a hyperbolic pattern with F 1+2 levels decreasing progressively and significantly as a function of increasing INR up to 3.0. A further decrease in F 1+2 levels observed at INR up to 4.0 was not statistically significant. At INR greater than 4.0, F 1+2 reached a plateau, with mean levels not significantly different for patients at increasing INR up to 9.0. Since the risk of bleeding increases at INR greater than 4.5, our results suggest that F 1+2 is of little value to assess the hemorrhagic risk in patients on OAT.

Volltext

Referenzen

References
1 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for F2/F1+2 fragment and the thrombin-antithrombin complex. Blood 1982; 59: 1086-97.
2 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insight gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
3 Mannucci PM, Tripodi A, Bottasso B, Baudo F, Finazzi G, De Stefano V, Palareti G, Manotti C, Mazzucconi MG, Castaman G. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67: 200-2.
4 Tripodi A, Mannucci PM, Chantarangkul V, Bottasso B, Arbini AA, Della Bella S, Scorza R. Markers of procoagulant imbalance in patients with localized Melanomas and autoimmune disorders. Brit J Haematol 1993; 84: 670-4.
5 Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993; 81: 2958-63.
6 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
7 Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diathesis. J Clin Invest 1987; 80: 1535-44.
8 Mannucci PM, Bottasso B, Tripodi A. Prothrombin fragment 1+2 and intensity of treatment with oral anticoagulants. Thromb Haemost 1991; 66: 741.
9 Elias A, Bonfils S, Daoud-Elias M, Gauthier B, Sié P, Boccalon H, Boneu B. Influence of long term oral anticoagulants upon prothrombin fragment 1+2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost 1993; 69: 302-5.
10 Takahashi H, Wada K, Satoh N, Takakuwa E, Furuta R, Yoshino N, Shibata A. Evaluation of oral anticoagulant therapy by measuring plasma prothrombin fragment 1+2. Blood Coag Fibrinol 1993; 69: 302-5.
11 Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring ”mini-intensity” anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F 1+2 levels. Blood 1992; 79: 2034-8.
12 van Wersch JWJ, Van Mourik-Alderliesten CH, Coremans A. Determination of markers of coagulation activation and reactive fibrinolysis in patients with mechanical heart valve prosthesis at different intensities of anticoagulation. Blood Coag Fibr 1992; 3: 183-6.
13 Estivals M, Pelzer H, Sié P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1+2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991; 78: 421-4.
14 Draper N, Smith M. Applied regression analysis. Wiley; New York: 1966
15 SAS (1990) SAS/STAT. Version 6, 4th Edition. SAS Institute Inc.; Cary NC:
16 Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness and optimal therpeutic range. Chest 1995; 108 (Suppl): 231-45.
17 Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-9.
18 Solymoss S, Bovill EG. Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation. Am J Clin Pathol 1996; 105: 293-7.
19 Barcellona D, Biondi G, Mameli G, Marongiu F. Are prothrombin fragment 1+2 and thrombin-antithrombin complexes useful in the management of oral anticoagulant therapy?. Int J Clin Lab Res 1997; 27: 76-8.
20 Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. New Engl J Med 1995; 333: 11-7.
21 Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.